Table of Content

Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT INDUSTRY
2.1 Summary about Familial Adenomatous Polyposis Treatment Industry
2.2 Familial Adenomatous Polyposis Treatment Market Trends
2.2.1 Familial Adenomatous Polyposis Treatment Production & Consumption Trends
2.2.2 Familial Adenomatous Polyposis Treatment Demand Structure Trends
2.3 Familial Adenomatous Polyposis Treatment Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Icosapent
4.2.2 Eflornithine Hydrochloride
4.2.3 Aspirin
4.2.4 CEQ-508
4.2.5 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Clinic
4.3.2 Hospital
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Icosapent
5.2.2 Eflornithine Hydrochloride
5.2.3 Aspirin
5.2.4 CEQ-508
5.2.5 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Clinic
5.3.2 Hospital
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Icosapent
6.2.2 Eflornithine Hydrochloride
6.2.3 Aspirin
6.2.4 CEQ-508
6.2.5 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Clinic
6.3.2 Hospital
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Icosapent
7.2.2 Eflornithine Hydrochloride
7.2.3 Aspirin
7.2.4 CEQ-508
7.2.5 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Clinic
7.3.2 Hospital
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Icosapent
8.2.2 Eflornithine Hydrochloride
8.2.3 Aspirin
8.2.4 CEQ-508
8.2.5 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Clinic
8.3.2 Hospital
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Icosapent
9.2.2 Eflornithine Hydrochloride
9.2.3 Aspirin
9.2.4 CEQ-508
9.2.5 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Clinic
9.3.2 Hospital
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Cancer Prevention Pharmaceuticals Inc
10.1.2 Marina Biotech Inc
10.1.3 Thetis Pharmaceuticals LLC
10.2 Familial Adenomatous Polyposis Treatment Sales Date of Major Players (2017-2020e)
10.2.1 Cancer Prevention Pharmaceuticals Inc
10.2.2 Marina Biotech Inc
10.2.3 Thetis Pharmaceuticals LLC
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT

List of Figure

List of Table
Table Familial Adenomatous Polyposis Treatment Product Type Overview
Table Familial Adenomatous Polyposis Treatment Product Type Market Share List
Table Familial Adenomatous Polyposis Treatment Product Type of Major Players
Table Brief Introduction of Cancer Prevention Pharmaceuticals Inc
Table Brief Introduction of Marina Biotech Inc
Table Brief Introduction of Thetis Pharmaceuticals LLC
Table Products & Services of Cancer Prevention Pharmaceuticals Inc
Table Products & Services of Marina Biotech Inc
Table Products & Services of Thetis Pharmaceuticals LLC
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Familial Adenomatous Polyposis Treatment Market Forecast (Million USD) by Region 2021f-2026f
Table Global Familial Adenomatous Polyposis Treatment Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Familial Adenomatous Polyposis Treatment Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Familial Adenomatous Polyposis Treatment Market Forecast (Million USD) Share by Demand 2021f-2026f